文献速递高血压心律失常瓣膜病与结构性心脏病

心脏副神经节瘤评估与管理的综合综述

Comprehensive review of evaluation and management of cardiac paragangliomas.
PubMed 文献 · Heart · 2020-05-22

心脏副神经节瘤是一种罕见神经内分泌肿瘤,去甲肾上腺素分泌可致严重高血压、心悸、致命性快速心律失常、卒中和晕厥。综述强调去甲肾上腺素代谢物甲氧基去甲肾上腺素为生化金标准,心脏CT、MRI和经胸超声心动图提供精确解剖信息,68Ga-DOTA-Tyr3-奥曲肽PET/CT具有最佳诊断准确性并有助于分期和排除转移。患者应进行基因检测,尤其是琥珀酸脱氢酶亚基基因突变。在充分α和β肾上腺素受体阻滞后行根治性手术是主要治疗策略。

要点

  • 去甲肾上腺素分泌需α和β肾上腺素受体阻滞以避免灾难性后果。
  • 甲氧基去甲肾上腺素是当前生化诊断金标准。
  • 68Ga-DOTA-Tyr3-奥曲肽PET/CT提供最佳诊断准确性并助分期。

核心结论

  • 心脏副神经节瘤患者需心内科医生作为多学科团队核心成员,掌握早期诊断和管理知识以优化结局。

研究设计与样本

  • 综述性文章,未报告系统检索范围与样本量。

主要发现

  • 去甲肾上腺素分泌可导致严重高血压、心悸、致命性快速心律失常、卒中和晕厥。
  • 心血管结构受压可导致缺血、心绞痛、非去甲肾上腺素能心律失常、心功能障碍或衰竭。

关键数值与推荐

  • 甲氧基去甲肾上腺素是当前生化诊断金标准。
  • 心脏CT、MRI和经胸超声心动图用于精确解剖信息。
  • 68Ga-DOTA-Tyr3-奥曲肽PET/CT提供最佳心脏副神经节瘤特异性诊断准确性,助分期和排除转移。
  • 基因检测尤其针对琥珀酸脱氢酶亚基基因突变。
  • 去甲肾上腺素分泌肿瘤在充分α和β肾上腺素受体阻滞后行根治性手术是主要治疗策略。

临床怎么用

  • 对疑似心脏副神经节瘤患者,检测甲氧基去甲肾上腺素并进行心脏CT、MRI和经胸超声心动图评估。
  • 使用68Ga-DOTA-Tyr3-奥曲肽PET/CT进行精确诊断、分期和排除转移。
  • 所有患者应接受基因检测,尤其是琥珀酸脱氢酶亚基基因。
  • 去甲肾上腺素分泌肿瘤术前使用α和β肾上腺素受体阻滞,然后行根治性手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac paraganglioma (PGL) is a rare neuroendocrine tumour causing significant morbidity primarily due to norepinephrine secretion potentially causing severe hypertension, palpitations, lethal tachyarrhythmias, stroke and syncope. Cardiologists are faced with two clinical scenarios. The first is the elevated norepinephrine, whose actions must be properly counteracted by adrenoceptor blockade to avoid catastrophic consequences. The second is to evaluate the precise location of a cardiac PGL and its spread since compression of cardiovascular structures may result in ischaemia, angina, non-noradrenergic-induced arrhythmia, cardiac dysfunction or failure. Thus, appropriate assessment of elevated norepinephrine by its metabolite normetanephrine is a gold biochemical standard at present. Furthermore, dedicated cardiac CT, MRI and transthoracic echocardiogram are necessary for the precise anatomic information of cardiac PGL. Moreover, a cardiologist needs to be aware of advanced functional imaging using 68Ga-DOTA(0)-Tyr(3)-octreotide positron emission tomography/CT, which offers the best cardiac PGL-specific diagnostic accuracy and helps to stage and rule out metastasis, determining the next therapeutic strategies. Patients should also undergo genetic testing, especially for mutations in genes encoding succinate dehydrogenase enzyme subunits that are most commonly present as a genetic cause of these tumours. Curative surgical resection after appropriate α-adrenoceptor and β-adrenoceptor blockade in norepinephrine-secreting tumours is the primary therapeutic strategy. Therefore, appropriate and up-to-date knowledge about early diagnosis and management of cardiac PGLs is paramount for optimal outcomes in patients where a cardiologist is an essential team member of a multidisciplinary team in its management.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Tella SH, Jha A, Taïeb D, et al. Comprehensive review of evaluation and management of cardiac paragangliomas. Heart. 2020. PMID: 32444502. doi:10.1136/heartjnl-2020-316540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。